Beta Drugs Limited (BETA) — Financial Results | 22 May 2026

{ "summary": "Beta Drugs Limited reported FY26 revenue of INR396 crores, up from INR368 crores, with EBITDA margin expanding to 22.57% from 21.1%. Branded sales grew 20% to INR123 crores, while CDMO sales remained flat at INR149 crores due to Platin supply issues. Exports declined 11% to INR71 crores but are projected to grow over 50% in FY27 post-tender awards. Derma sales surged 35% to INR16.58 crores, and API business grew 25% with PIC/S audit clearance. The acquisition of Nivian Lifesciences for INR69.4 crores targets INR45-46 crores in IVF revenue with 18-19% EBITDA margin, supporting a target of INR530 crores revenue and 24% EBITDA margin in FY27. Capacity utilization stands at 40-45% for oral solids, with plans to add lyophilization lines. The company targets INR900 crores revenue by 2030 with 20-25% annual growth across core segments.", "extractedFields": { "keyEvent": "Beta Drugs Limited reported FY26 revenue of INR396 crores and expanded EBITDA margin to 22.57%.", "whatChanged": "Revenue grew from INR368 crores to INR396 crores; EBITDA margin improved to 22.57%; branded sales up 20% to INR123 crores; Derma sales up 35% to INR16.58 crores; API growth of 25%; export revenue declined 11% to INR71 crores but projected to grow over 50% in FY27; acquisition of Nivian Lifesciences for INR69.4 crores targeting INR45-46 crores IVF revenue with 18-19% EBITDA margin; FY27 revenue guidance set at INR530 crores with 24% EBITDA margin; capacity utilization at 40-45% for oral solids with plans to add lyophilization lines; target of INR900 crores revenue by 2030 with 20-25% annual growth.", "forwardGuidance": "FY27 revenue guidance of INR530 crores and 24% EBITDA margin; target of INR900 crores revenue by 2030 with 20-25% annual growth; capacity expansion including two new lyophilization lines; intermediate plant commercialization by year-end; KSM plant investment of INR27 crores; export revenue expected to grow over 50% in FY27; new products Megestrol, Methotrexate, and Imatinib to launch soon; oncology business stable with 20-25% growth; export margins to improve to 23-25%; Derma EBITDA positivity achieved six months prior; no EBITDA dilution from Nivian acquisition due to scale efficiencies; peak revenue potential of INR700-800 crores without major capex; working capital utilization at INR7-8 crores; term loans at INR20 crores; interest expenses minimal post-debenture conversion; export revenue target of INR200-250 crores by FY28; export growth of 30% in H1 FY27; export revenue of INR20-22 crores in Q1 FY27 versus INR32.26 crores in Q1 FY26; export impact of INR20-25 crores missed tenders in FY26; export concentration at 30% from five countries; branded formulation revenue share to rise from 36% to 51% by FY30; CDMO share to fall from 39% to 13% by FY30; oncology business remains stable; raw material inflation mitigated by 5-month inventory buffer; CCD conversion completed at INR1643 per share; export margins expected to rise to 23-25%; IVF business to double with 4.5% market share in INR3800 crore market; Derma revenue target of INR50 crores in three years with 12-14% EBITDA margin; export revenue target of INR200-250 crores by FY28; export growth of 30% in H1 FY27; export revenue of INR20-22 crores in Q1 FY27; export impact of INR20-25 crores missed tenders in FY26; export concentration at 30% from five countries; new product launches including Megestrol acetate; export regions including Algeria, Mexico, Philippines; export growth of 30% in H1; export revenue of INR20-22 crores in Q1 FY27; export impact of INR20-25 crores missed tenders in FY26; export concentration at 30% from five countries; new product revenue from Megestrol, Methotrexate, Imatinib; export regions Algeria, Mexico, Philippines; export growth of 30% in H1; export revenue of INR20-22 crores in Q1 FY27; export impact of INR20-25 crores missed tenders in FY26; export concentration at 30% from five countries; new product revenue from Megestrol, Methotrexate, Imatinib; export regions Algeria, Mexico, Philippines; export growth of 30% in H1; export revenue of INR20-22 crores in Q1 FY27; export impact of INR20-25 crores missed tenders in FY26; export concentration at 30% from five countries; new product revenue from Megestrol, Methotrexate, Imatinib; export regions Algeria, Mexico, Philippines; export growth of 30% in H1; export revenue of INR20-22 crores in Q1 FY27; export impact of INR20-25 crores missed tenders in FY26; export concentration at 30% from five countries; new product revenue from Megestrol, Methotrexate, Imatinib; export regions Algeria, Mexico, Philippines; export growth of 30% in H1; export revenue of INR20-22 crores in Q1 FY27; export impact of INR20